Advocacy intelligence hub — real-time data for patient organizations
Respigam: FDA approved
For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Respigam
MedImmune & Massachussetts Public Health Biologics Labs.
Respigam
(Respiratory syncytial virus immune globulin (Human))Orphan drugMedImmune & Massachussetts Public Health Biologics Labs.
Browse all Susceptibility to respiratory infections associated with CD8alpha chain mutation news →